{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:27:11Z","timestamp":1788982031939,"version":"build-2803163510"},"reference-count":67,"publisher":"Bioscientifica","issue":"9","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroendocrine neoplasms (NENs) are a highly heterogeneous group of tumors originating from the neuroendocrine system, predominantly occurring in the gastrointestinal tract and lungs. This meta-analysis aimed to clarify the association of programmed death 1 (PD-1)\/programmed death-ligand 1 (PD-L1) expression with clinicopathological parameters and prognosis in patients with digestive system NENs. A systematic literature search was performed in PubMed, Web of Science, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Biomedical Literature Database (CBM) from each database\u2019s inception to February 2026. Eligible studies were analyzed using Stata 17.0 software, with 29 studies including 2,633 patients. Results showed no significant association between PD-1 expression and clinicopathological parameters or prognosis. In contrast, PD-L1 expression was closely correlated with high tumor grade (OR = 2.73, 95% CI: 1.33\u20135.60, P = 0.006) and pancreatic primary tumor site (OR = 2.58, 95% CI: 1.21\u20135.52, P = 0.014). Regarding prognosis, positive PD-L1 expression was associated with inferior overall survival (OS) in gastroenteropancreatic NENs (GEP-NENs) (HR = 1.77, 95% CI: 1.25\u20132.51, P = 0.001) but favorable OS in esophageal NENs (HR = 0.60, 95% CI: 0.37\u20130.99, P = 0.047). In conclusion, PD-L1 expression correlates with high tumor grade and pancreatic origin. It serves as a predictive biomarker for poor OS in GEP-NENs but favorable prognosis in esophageal NENs, highlighting the divergent prognostic value of the PD-1\/PD-L1 axis across digestive system NEN subtypes. These findings provide hypothesis-generating evidence for the potential rationale of immune checkpoint inhibitors in high-grade or poorly differentiated GEP-NENs, although their clinical application requires further prospective validation.<\/jats:p>","DOI":"10.1530\/erc-26-0145","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:50:53Z","timestamp":1787604653000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Association between PD-1\/PD-L1 expression and clinicopathological parameters as well as prognosis in neuroendocrine neoplasms of the digestive system: a systematic review and meta-analysis"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-2054","authenticated-orcid":true,"given":"Qiming","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Liver Transplantation, First Central Hospital of Tianjin Medical University 1 , ,","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital 2 , ,","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital 3 , ,","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory for Organ Transplantation, Tianjin First Center Hospital 4 , ,","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Liver Transplantation, First Central Hospital of Tianjin Medical University 1 , ,","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Liver Transplantation, Tianjin First Central Hospital 2 , ,","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Liver Transplantation, First Central Hospital of Tianjin Medical University 1 , ,","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital 2 , ,","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital 3 , ,","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory for Organ Transplantation, Tianjin First Center Hospital 4 , ,","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Liver Transplantation, First Central Hospital of Tianjin Medical University 1 , ,","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital 2 , ,","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital 3 , ,","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory for Organ Transplantation, Tianjin First Center Hospital 4 , ,","place":["Tianjin, China"]},{"name":"Institute of Transplantation Medicine, Nankai University 5 , ,","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026090915015687600_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/path.6291","article-title":"PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas","volume":"263","author":"Cubiella","year":"2024","journal-title":"J Pathol"},{"key":"2026090915015687600_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2025.07.004","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"170","author":"Vijayvergia","year":"2026","journal-title":"Gastroenterology"},{"key":"2026090915015687600_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejca.2022.06.003","article-title":"Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study","volume":"172","author":"Pole\u00e9","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026090915015687600_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"key":"2026090915015687600_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188804","article-title":"Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations","volume":"1877","author":"Pozas","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026090915015687600_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ijc.35372","article-title":"Incidence trends and relative survival of colorectal neuroendocrine neoplasms: a population-based study using German cancer registry data","volume":"157","author":"M\u00f6ller","year":"2025","journal-title":"Int J Cancer"},{"key":"2026090915015687600_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41416-024-02773-w","article-title":"Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms","volume":"131","author":"Elvebakken","year":"2024","journal-title":"Br J Cancer"},{"key":"2026090915015687600_bib8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2024.4330","article-title":"Biomarkers to inform prognosis and treatment for unresectable or metastatic GEP-NENs","volume":"10","author":"Loree","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026090915015687600_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120540119","article-title":"Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1","volume":"119","author":"Oreskovic","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090915015687600_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2022.108911","article-title":"Mathematical modeling for the combination treatment of IFN-\u03b3 and anti-PD-1 in cancer immunotherapy","volume":"353","author":"Liao","year":"2022","journal-title":"Math Biosci"},{"key":"2026090915015687600_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.32074\/1591-951X-803","article-title":"PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application","volume":"114","author":"Mastracci","year":"2022","journal-title":"Pathologica"},{"key":"2026090915015687600_bib12","article-title":"Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors","volume":"16","author":"Yan","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"2026090915015687600_bib13","first-page":"6068","article-title":"Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies","volume":"16","author":"Yang","year":"2024","journal-title":"Aging"},{"key":"2026090915015687600_bib14","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.932146","article-title":"Relationship of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) polymorphisms with overall cancer susceptibility: an updated meta-analysis of 28 studies with 60 612 subjects","volume":"27","author":"Zhang","year":"2021","journal-title":"Med Sci Monit"},{"key":"2026090915015687600_bib15","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.3390\/cancers12113448","article-title":"Immunoprofiling in neuroendocrine neoplasms Unveil immunosuppressive microenvironment","volume":"12","author":"Busse","year":"2020","journal-title":"Cancers"},{"key":"2026090915015687600_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36129-1","article-title":"Analysis of expression of the PD-1\/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors","volume":"8","author":"Sampedro-N\u00fa\u00f1ez","year":"2018","journal-title":"Sci Rep"},{"key":"2026090915015687600_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243900","article-title":"PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3","volume":"15","author":"Ali","year":"2020","journal-title":"PLoS One"},{"key":"2026090915015687600_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101526","article-title":"Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data","volume":"25","author":"R\u00f6sner","year":"2022","journal-title":"Transl Oncol"},{"key":"2026090915015687600_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026090915015687600_bib20","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"2026090915015687600_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"2026090915015687600_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2026090915015687600_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2026090915015687600_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/ERC-18-0494","article-title":"Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia","volume":"26","author":"B\u00f6sch","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026090915015687600_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1159\/000503722","article-title":"Gastroenteropancreatic high-grade neuroendocrine neoplasms: histology and molecular analysis, two sides of the same coin","volume":"110","author":"Busico","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2026090915015687600_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.401","article-title":"Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading","volume":"8","author":"Cavalcanti","year":"2017","journal-title":"Cell Death Dis"},{"key":"2026090915015687600_bib27","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/jcm10081741","article-title":"Myeloid and T-cell microenvironment immune features identify two prognostic sub-groups in high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"10","author":"Centonze","year":"2021","journal-title":"J Clin Med"},{"key":"2026090915015687600_bib28","article-title":"The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"2026090915015687600_bib29","first-page":"4737","article-title":"Differences in clinicopathology and prognosis between gastroesophageal junctional and gastric non-cardiac neuroendocrine carcinomas: a retrospective comparison study of consecutive 56 cases from a single institution in China","volume":"12","author":"Cheng","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2026090915015687600_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/ERC-18-0189","article-title":"Analysis of the immune landscape of small bowel neuroendocrine tumors","volume":"26","author":"Cives","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026090915015687600_bib31","volume-title":"Significance of MMRs and PD-L1 Expression in Gastrointestinal Neuroendocrine Tumors and its Relationship with Prognosis [D]","author":"Guo","year":"2020"},{"key":"2026090915015687600_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/07357907.2024.2330102","article-title":"Retrospective analyses of PD-L1, LAG-3, TIM-3, OX40L expressions and MSI status in gastroenteropancreatic neuroendocrine neoplasms","volume":"42","author":"G\u00fcrler","year":"2024","journal-title":"Cancer Invest"},{"key":"2026090915015687600_bib33","volume-title":"Microsatellite Instability, Expression of PD-1 and PD-L1 in Pancreatic Neuroendocrine Neoplasm and their Correlation with Prognosis [D]","author":"Hao","year":"2020"},{"key":"2026090915015687600_bib34","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2169\/internalmedicine.5648-20","article-title":"Pathological findings of the host immune reaction in the tumor microenvironment of gastroenteropancreatic neuroendocrine neoplasms","volume":"60","author":"Hasegawa","year":"2021","journal-title":"Intern Med"},{"key":"2026090915015687600_bib35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.21037\/tcr.2016.07.13","article-title":"Programmed cell death-ligand 1 expression and its prognostic significance in completely resected primary small cell carcinoma of esophagus","volume":"5","author":"Huang","year":"2016","journal-title":"Transl Cancer Res"},{"key":"2026090915015687600_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7150\/jca.13711","article-title":"The impact of PD-L1 expression in patients with metastatic GEP-NETs","volume":"7","author":"Kim","year":"2016","journal-title":"J Cancer"},{"key":"2026090915015687600_bib37","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000842","article-title":"Expression patterns of immune checkpoint molecules and their clinical values in gastric neuroendocrine neoplasms","volume":"16","author":"Liang","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"2026090915015687600_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cjp2.135","article-title":"Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms","volume":"5","author":"Milione","year":"2019","journal-title":"J Pathol Clin Res"},{"key":"2026090915015687600_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5858\/arpa.2021-0377-OA","article-title":"Expression and prognostic value of B7 family immune checkpoints in pancreatic neuroendocrine tumors","volume":"147","author":"Mo","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"2026090915015687600_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00428-024-03825-5","article-title":"PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as theragnostic and prognostic biomarkers","volume":"485","author":"Multone","year":"2024","journal-title":"Virchows Arch"},{"key":"2026090915015687600_bib41","first-page":"779","article-title":"Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors","volume":"24","author":"Oktay","year":"2019","journal-title":"J Buon"},{"key":"2026090915015687600_bib42","first-page":"2123","article-title":"Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: a retrospective study of 136 patients","volume":"15","author":"Ono","year":"2018","journal-title":"Oncol Lett"},{"key":"2026090915015687600_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.humpath.2017.10.003","article-title":"Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1\/PD-L1 therapy","volume":"70","author":"Roberts","year":"2017","journal-title":"Hum Pathol"},{"key":"2026090915015687600_bib44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1530\/ERC-21-0223","article-title":"Antitumor immune response is associated with favorable survival in GEP-NEN G3","volume":"28","author":"Rosery","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026090915015687600_bib45","first-page":"448","article-title":"The clinical significance of PD-L1\/PD-1 expression in gastroenteropancreatic neuroendocrine neoplasia","volume":"49","author":"Wang","year":"2019","journal-title":"Ann Clin Lab Sci"},{"key":"2026090915015687600_bib46","first-page":"2013","article-title":"Correlation between microsatellite status and PD-L1 expression in gastrointestinal pan-creatic neuroendocrine tumors and its clinical significance","volume":"38","author":"Wang","year":"2023","journal-title":"Pract J Cancer"},{"key":"2026090915015687600_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8884683","article-title":"Tumor-infiltrating immune cells and PD-L1 as prognostic biomarkers in primary esophageal small cell carcinoma","volume":"2020","author":"Wu","year":"2020","journal-title":"J Immunol Res"},{"key":"2026090915015687600_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fonc.2020.00132","article-title":"Immune checkpoint markers in neuroendocrine carcinoma of the digestive system","volume":"10","author":"Xing","year":"2020","journal-title":"Front Oncol"},{"key":"2026090915015687600_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/his.14230","article-title":"Programmed cell death protein 1\/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma","volume":"78","author":"Yamashita","year":"2021","journal-title":"Histopathology"},{"key":"2026090915015687600_bib50","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/his.14924","article-title":"PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma","volume":"83","author":"Yamashita","year":"2023","journal-title":"Histopathology"},{"key":"2026090915015687600_bib51","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3748\/wjg.v25.i14.1684","article-title":"Clinical significance of programmed death 1\/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas","volume":"25","author":"Yang","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2026090915015687600_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-20-0382","article-title":"Spartalizumab in metastatic, well\/poorly differentiated neuroendocrine neoplasms","volume":"28","author":"Yao","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026090915015687600_bib53","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12022-024-09835-y","article-title":"Progression of low-grade neuroendocrine tumors (NET) to high-grade neoplasms Harboring the NEC-like co-alteration of RB1 and TP53","volume":"35","author":"Joseph","year":"2024","journal-title":"Endocr Pathol"},{"key":"2026090915015687600_bib54","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s11547-021-01408-x","article-title":"Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging","volume":"126","author":"Danti","year":"2021","journal-title":"Radiol Med"},{"key":"2026090915015687600_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13454","article-title":"Liver metastases in high-grade neuroendocrine neoplasms: a comparative study of hepatic tumor volume and biochemical findings in NET G3 versus NEC","volume":"36","author":"Melhorn","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026090915015687600_bib56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/ERC-17-0427","article-title":"Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors","volume":"25","author":"Kasajima","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026090915015687600_bib57","first-page":"1","article-title":"Prognostic analysis and expression patterns of programmed cell death ligand 1 and BRAF V600E in esophageal neuroendocrine carcinoma","volume":"31","author":"Zhang","year":"2025","journal-title":"Oncol Lett"},{"key":"2026090915015687600_bib58","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cancers15061732","article-title":"Analysis of the clinicopathological characteristics, prognosis, and lymphocyte infiltration of esophageal neuroendocrine neoplasms: a surgery-based cohort and propensity-score matching study","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"key":"2026090915015687600_bib59","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1097\/JS9.0000000000000064","article-title":"Patterns and prognostic values of programmed cell death-ligand 1 expression and CD8 + T-cell infiltration in small cell carcinoma of the esophagus: a retrospective analysis of 34 years of National Cancer Center data in China","volume":"110","author":"Zhang","year":"2024","journal-title":"Int J Surg"},{"key":"2026090915015687600_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1173","article-title":"Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"2026090915015687600_bib61","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026090915015687600_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103249","article-title":"Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study","volume":"84","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026090915015687600_bib63","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00262-025-04038-8","article-title":"Cadonilimab, a PD-1\/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study","volume":"74","author":"Wang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026090915015687600_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100364","article-title":"Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms","volume":"7","author":"Al-Toubah","year":"2022","journal-title":"ESMO Open"},{"key":"2026090915015687600_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114768","article-title":"Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80\/PD-L1 interaction","volume":"43","author":"Robinson","year":"2024","journal-title":"Cell Rep"},{"key":"2026090915015687600_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1400841","article-title":"Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis","volume":"15","author":"van der Leij","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026090915015687600_bib67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13000-018-0712-1","article-title":"Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors","volume":"13","author":"Wang","year":"2018","journal-title":"Diagn Pathol"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0145\/524154\/erc-26-0145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0145\/524154\/erc-26-0145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:02:35Z","timestamp":1788980555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/9\/e260145\/78070\/Association-between-PD-1-PD-L1-expression-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0145","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"e260145"}}